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The trimodality approach represented by concurrent chemoradiotherapy followed by surgical resection is a highly effective, but
potentially toxic therapy for locally advanced non-small-cell lung cancer (NSCLC). In this review, we discuss the current status of this
therapy in patients with mediastinal node-positive (N2) stage III NSCLC or superior sulcus tumor, and present an overview of the
principles for optimisation of the risk/benefit. Numerous clinical questions remain, and enrolment of patients into well-designed
clinical trials should be encouraged.
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Lung cancer is the leading cause of death from cancer in Japan as
well as in other industrialised nations. Non-small-cell lung cancer
(NSCLC) accounts for about 80% of all cases.
About one-third of all cases of NSCLC present with locally
advanced, stage IIIA/IIIB disease, most frequently with mediastinal
node involvement (N2). Surgical resection was employed as
‘standard’ therapy for relatively less advanced ‘resectable’ cases
with N2 NSCLC; however, the prognosis was not favourable
(Suzuki et al, 1999). For more advanced, ‘bulky’ unresectable N2
disease, neither satisfactory local control nor satisfactory suppres-
sion of micrometastases was achieved with definitive thoracic
radiotherapy (Schaake-Koning et al, 1992; Dillman et al, 1996).
Systemic chemotherapy was introduced two decades ago for
cases with stage III N2 NSCLC (Le Chevalier et al, 1991; Schaake-
Koning et al, 1992; Sause et al, 1995; Dillman et al, 1996), aimed at
both eradication of micrometastases and improvement of local
control. A multimodality approach to treatment, for example,
systemic chemotherapy combined with definitive local therapy, is
now the most preferred approach in the battle against stage III
NSCLC. In particular, trimodality therapy, combining surgery,
radiotherapy and chemotherapy, has been intensively investigated
often with promising results. The sequence of ‘trimodality’ therapy
that has most often been employed is induction chemoradio-
therapy, followed by surgical resection, with or without consolida-
tion chemotherapy. Although such therapy has sometimes been
shown to be highly effective, it is also highly toxic, with a reported
treatment-related death rate of as high as 10%. Careful evaluation
of the risk/benefit ratio of such therapy is thus indispensable.
On the other hand, a small subset of NSCLC called superior
sulcus tumour (SST) or Pancoast’s tumour, in which the tumor
is located in the superior sulcus and involves structures at the
thoracic inlet, has posed a challenging problem for surgeons,
radiation oncologists and medical oncologists alike, ever since it
was first discovered (Rusch et al, 2001). However, the trimodality
approach mentioned above has been shown to be associated with a
relatively more favourable risk/benefit ratio in this subset of
patients, for whom it currently appears to be the treatment of first
choice (Rusch et al, 2001; Kunitoh et al, 2003).
In this study, we review the current data on the use of the
trimodality approach in the treatment of patients with locally
advanced NSCLC, and also discuss means to optimise the
treatment using this approach.
RATIONALES FOR TRIMODALITY THERAPY
Although the strongest rationale for the use of the trimodality
therapy stems from the promising results of clinical phase II data,
upfront systemic chemotherapy offers several practical as well
as theoretical advantages (Pisters et al, 2000). Early introduction
of systemic therapy may be expected to lead to early control of
micrometastases. Response to the therapy can be easily assessed by
radiographic imaging, which can help physicians avoid unneces-
sary, ineffective therapy. Visualisation of the response could
motivate the patients to accept additional potentially toxic therapy,
which cannot be said for postoperative chemotherapy. In addition,
as compared to the postoperative status, pre-operative patients are
usually in a much fitter state for chemotherapy.
Addition of radiotherapy to preoperative chemotherapy should
mainly be considered for local control (Furuse et al, 1999). It has
been observed that at the time of surgery, clinical N2 NSCLCs and
SSTs are often even more advanced in stage than was expected
preoperatively, and the complete resection rates are not suffi-
ciently satisfactory. With the addition of radiotherapy, a greater
tumour response can be expected, with the hope of better local
control. Hypothetical dissemination of tumour cells during surgery
may also be prevented.
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www.bjcancer.comTOXICITY OF THE CHEMORADIOTHERAPY
Concurrent chemoradiotherapy is often employed as induction
therapy in the trimodality approach. As compared with chemo-
therapy alone or sequential chemoradiotherapy, concurrent
chemoradiotherapy has been associated with a higher incidence
of haematologic and oesophageal toxicities (Furuse et al, 1999).
However, the toxicity has generally been reported to be manage-
able, with few deaths related to treatment toxicity.
In some trials, patients undergoing definitive surgery have
received a couple of courses of consolidation chemotherapy after
operation. However, the compliance rate for this strategy was
reported to be poor (Pisters et al, 2000; Rusch et al, 2001). In
addition, some deaths related to drug toxicity have also been
reported during the consolidation phase (Albain et al, 2005),
prompting further questioning of its benefits. The role of
consolidation therapy after surgery, therefore, still remains to be
established.
SURGICAL PROBLEMS IN THE TRIMODALITY
APPROACH AND THEIR MANAGEMENT
Surgical resection adopted in the trimodal treatment approach is
limited exclusively to a major lung resection such as lobectomy or
pneumonectomy. As trimodality treatment is usually indicated for
stage IIIA or IIIB disease, hilar and mediastinal lymph node
dissection is also mandatory. Although preoperative chemo-
radiotherapy could yield better locoregional control, it would also
result in a ‘frozen’ hilum and/or mediastinum. Sometimes very
effective induction treatment may make it that much more difficult
for the thoracic surgeon to dissect the hilum and mediastinum.
Prior evaluation of the mediastinal lymph nodes by mediastino-
scopy is often necessary, and this procedure also leads to a local
fibrosis, which makes surgical dissection difficult. The surgical
mortality associated with pneumonectomy and lobectomy without
prior induction treatment has been reported to vary from 3.1 to
17.0, and 0.3 to 10.1%, respectively (Watanabe et al, 2004). On the
other hand, when they are performed after induction chemo-
radiotherapy, the surgical mortality is markedly increased for both
procedures (Table 1).
The ability to safely perform major lung resection following
induction chemoradiotherapy would depend on several factors.
Among the most important is to secure the major vessels
intraoperatively. Preoperative induction treatment would melt
hilar and/or mediastinal lymph nodes. As a result, these lymph
nodes often become adherent to major vessels, making dissection
difficult. Dissection of such lymph nodes adhering to vessels
without the utmost care could lead to massive intraoperative
bleeding. In such a situation, the major vessels, such as the
pulmonary artery and vein, should be clamped proximally and
distally to prepare for an unforeseen massive bleeding. Thoracic
surgeons must not hasten to dissect such nodes. Martin et al
(2001) reported three significant predictors of the postoperative
complications: intraoperative blood loss, forced expiratory volume
in the first second (percent predicted), and right pneumonectomy.
Thus, thoracic surgeon must attempt their utmost to control and
minimise intraoperative bleeding.
Second, the risk of bronchopleural fistula, one of the fatal
complications, should be borne in mind. To prepare for
minimising the risk of development of bronchopleural fistula,
Stamatis et al (2002) recommended a reinforcement of the
bronchial stump (Eberhardt et al, 1998). They have used
thymus/mediastinal fat (89%) to cover the bronchial stump, and
reported favourable results. Other materials for covering the stump
include an intercostal muscle flap or diaphragmatic flap. They
reported that none of their patients developed bronchopleural
fistula ever since they adopted routine coverage of the bronchial
stump with a vital flap. Bronchopleural fistula has been reported to
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British Journal of Cancer (2007) 96(10), 1498–1503 & 2007 Cancer Research UKdevelop in 0–15% of surgical patients receiving trimodality
treatment. This fatal complication occurs more frequently in cases
undergoing pneumonectomy, especially right pneumonectomy.
Thus, coverage of the bronchial stump is strongly recommended in
cases undergoing right pneumonectomy. Omentopexy may some-
times be indicated.
Finally, avoidance of postoperative pulmonary oedema is
important. We usually restrict fluid administration and institute
aggressive diuretic therapy postoperatively for at least first 3 days.
Some recommend the use of a steroid postoperatively to avoid
pulmonary oedema (Eberhardt et al, 1998; Stamatis et al, 2002).
Right pneumonectomy has been reported from various studies
to be associated with very high morbidity/mortality (Table 1).
Therefore, when preoperative evaluation suggests the necessity
for right pneumonectomy to accomplish R0 surgery, for example,
for a tumour located in the lower lobe with bulky hilar nodes, the
indications for surgery must be evaluated very cautiously. Careful
assessment of pulmonary function, diffusion capacity, and a
quantitative ventilation scan would be necessary. Surgery should
be offered only to highly selected cases, and switching to another
treatment option, such as definitive chemoradiotherapy, must be
seriously considered and discussed with the patient.
Bronchovascular sleeve resection has been established as one of
the standard surgical procedures to spare the lung parenchyma
(Deslauriers et al, 2004). Although highly attractive in the
trimodality approach for lung cancer treatment, the feasibility of
this procedure after induction chemoradiotherapy, as well as its
efficacy, has yet to be confirmed.
Finally, it should be noted that surgical safety tends to be better
in single-institution reports (Table 1). Therefore, methods for
surgical quality control should be established for multi-institu-
tional settings.
SPECIFIC DISEASES
Stage III N2 disease
Standard treatment for N2 NSCLC Until the 1970s, the standard
treatment for N2 NSCLC had been surgery for ‘resectable’, and
definitive radiotherapy for ‘unresectable’ disease, although the
treatment results remained very poor, with few long-term
survivors. Neither preoperative nor postoperative radiotherapy
improved the outcome.
A series of small phase III trials showed that preoperative
platinum-based chemotherapy improved the survival in patients
with ‘resectable’ N2 disease (Rosell et al, 1994; Roth et al, 1994).
Although the results could not be reproduced in a larger
randomised trial (Depierre et al, 2002) in the same subset of N2
patients, the role of systemic chemotherapy remains unequivocal,
given the very high systemic relapse rate with local therapy alone.
More recent trials have shown that postoperative adjuvant
chemotherapy may improve the outcome in pathologically staged
N2 patients (The International Adjuvant Lung Cancer Trial
Collaborative Group, 2004; Douillard et al, 2006).
Platinum-based chemotherapy was also shown to improve the
survival of NSCLC patients with ‘unresectable’ N2 disease, when it
was added to definitive thoracic radiotherapy (Le Chevalier et al,
1991; Schaake-Koning et al, 1992; Sause et al, 1995; Dillman et al,
1996). Concurrent chemoradiotherapy was demonstrated to be
superior to sequential chemoradiotherapy (Furuse et al, 1999).
However, the optimal treatment strategy, including the roles of
induction/consolidation therapy as well as the most suitable
chemotherapy regimen remains undetermined.
With reports of the favourable outcome of concurrent
chemoradiotherapy in stage III NSCLC cases with N2 disease,
for which, therefore, this strategy now represents the standard
treatment, the definition of ‘resectable’ N2 disease has become
even more nebulous. In fact, surgery may not be indicated at all for
clinically suspected and pathologically confirmed (via mediastino-
scopy) N2 disease, even when the disease is technically ‘resectable’
(Albain et al, 2005).
Trimodality treatment for N2 NSCLC Most of the reports of the
usefulness of the trimodality approach for N2 NSCLC are based on
the results of phase II or retrospective trials of preoperative
chemoradiotherapy (Faber et al, 1989; Rusch et al, 1993; Deutsch
et al, 1994; Albain et al, 1995; Choi et al, 1997; Eberhardt et al,
1998; Katakami et al, 1998; Thomas et al, 1999; Doddoli et al, 2001;
Martin et al, 2001; Stamatis et al, 2002; Sonett et al, 2004; Cerfolio
et al, 2005; Daly et al, 2006). There are some highly promising and
encouraging reports of long-term survival rates of around 30%,
however, the toxicity is also substantial, usually exceeding that
observed with other multimodality therapy.
In view of the promising but controversial data, a few phase III
trials were conducted; the ‘control’ arms of the studies were
variable, reflecting the heterogeneity of N2 NSCLC, and conse-
quently, so were the ‘concepts’ of trimodality.
In some studies, the trimodality approach appeared to derive
from efforts to intensify preoperative induction chemotherapy.
Before 2001, two small-scale randomised trials reported the results
of trimodality vs induction chemotherapy for N2 NSCLC. The
results of neither trial, the one showing a positive (Fleck et al,
1993) and the other showing a negative (Sauvaget et al, 2000)
effect, have been published as full articles. More recently, another
larger trial from Germany compared preoperative chemoradio-
therapy with preoperative chemotherapy and postoperative radio-
therapy, and reported no significant differences in the results
(Semik et al, 2004). However, the actual issue should be viewed as
an evaluation of the timing or sequence of the therapy, rather than
as an investigation of the usefulness of the trimodality approach
itself. The ‘induction chemotherapy with or without radiotherapy’
concept has now been introduced in recently initiated trials in
North America and Europe.
The trimodality approach could be viewed as chemoradio-
therapy followed by salvage surgery of the residual tumour. A
large-scale US trial, INT0139, compared surgical resection and
boost radiotherapy, in patients with N2 NSCLC receiving induction
chemoradiotherapy (Albain et al, 2005). Although the progression-
free survival (PFS) rate favoured the surgery (trimodality) arm, the
overall survival rate was not statistically significantly different
between the two arms, with only a marginally larger number of
long-term survivors in the surgery arm.
Relapse pattern and its implications Local relapse as well as
emergence of distant metastases remains a big problem in N2
NSCLC patients treated by chemoradiotherapy. Concurrent
chemoradiotherapy was reported to be better for local control as
compared to sequential therapy (Furuse et al, 1999); however, the
locoregional relapse rate remained high. One of the aims of the
trimodality approach is to obtain better local control with surgical
resection. In fact, the local relapse rate appeared to have decreased,
especially in R0-surgery cases. In an intention-to-treat analysis,
‘local relapse only’ accounted for 10% of the cases showing disease
progression in the trimodality arm of INT0139 (Albain et al, 2005),
whereas it accounted for 22% of the cases showing disease
progression in the chemoradiotherapy arm (P¼0.002). However,
these figures might have been biased by competitive risks; as
the trimodality approach was associated with a larger number of
treatment-related deaths, and as it is plausible that cases at a
higher risk of postoperative morbidity/mortality were more likely
suffer from uncontrollable local tumours, the local control rate
with the trimodality approach could have been exaggerated by the
exclusion of these high-risk patients. In addition, clinical diagnosis
of failure of local control with chemoradiotherapy is often difficult
because of the confounding effect of radiation fibrosis, the
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tumours. It may not be worthwhile placing much emphasis on the
difference in relapse patterns among different modalities.
One of the major problems with the use of combined modality
treatment for locally advanced NSCLC is the high risk of brain
metastasis (Stuschke et al, 1999; Thomas et al, 1999). A substantial
proportion of patients undergoing successful R0 resection suffer
from brain-only relapse. A non-randomised observational study
suggested that prophylactic cranial irradiation (PCI) might reduce
the risk of brain metastasis in these patients (Stuschke et al, 1999).
Whether or not PCI would benefit optimally treated patients with
locally advanced NCLC is now under investigation in randomised
trials.
Prognostic and predictive factors Not surprisingly, complete
resection (R0 operation), which should be the aim of induction
chemoradiotherapy, is associated with a better prognosis. Besides,
eradication of tumour cells in the mediastinal nodes has also been
reported to be a favourable prognostic factor (Choi et al, 1997;
Albain et al, 2005). However, the problem is that the clinical
response to induction therapy as judged by CT imaging, seems to
be a poor predictor of the pathologic ‘downstaging’. There are
some reports that suggest that repeated mediastinoscopy should be
conducted to evaluate the status of the mediastinal nodes after
induction therapy and predict the postoperative outcomes (Mateu-
Navarro et al, 2000); however, this is not widely employed because
of the technical difficulties involved. FDG-PET is currently being
investigated as a promising tool for reliable assessment of the
response to treatment (Pottgen et al, 2006).
Pathological complete response (pCR), defined as absence of
viable cells in the resected specimen, has been reported to be a
good prognostic factor by some, but not others. Although pCR is
an established prognostic factor in patients receiving induction
chemotherapy, inclusion of radiotherapy is likely to modify the
information based on the locoregional response status on the effect
of systemic chemotherapy against micrometastases.
Evidently, these prognostic factors, which are associated with a
good response to induction therapy, would be associated with a
better outcome even without subsequent surgery. Therefore, these
are not necessarily predictive factors of the response to trimodality
treatment, that is, it is still unclear whether surgery might be more
beneficial in these patients. The only known ‘predictive’ factor of
the outcome of surgical resection, which is actually a negative
factor, is the necessity for pneumonectomy (Albain et al, 2005). An
exploratory subset analysis in INT0139 revealed that patients
undergoing pneumonectomy did poorly as compared to matched
controls. This is clearly due to excessive early toxic deaths after
pneumonectomy, in particular, right pneumonectomy or complex
left pneumonectomy (see surgical problems section above). This
surgical morbidity and mortality might well offset the advantage of
PFS in the trimodality arm.
Superior sulcus tumours
Superior sulcus tumours have long been treated by preoperative
radiation and resection, but both the curative resection (R0) rate
(50%) and the long-term survival rate (30%) have remained poor
and unchanged over the last 40 years (Rusch et al, 2001). Two
large-scale phase II trials from the US and Japan (Rusch et al, 2001;
Kunitoh et al, 2003) suggested that preoperative concurrent
chemoradiotherapy could improve the outcome in these patients.
In both series, the R0 rate was approximately 70%, with a 5-year
survival rate of 40–50%. The treatment-related death rate was
acceptably low at 4%.
Because of the infrequent occurrence of this tumour subtype, a
randomised trial would be extremely difficult. Therefore, given the
reproducibility of the favourable results as described above, the
trimodality approach may be accepted as the standard treatment
strategy for SSTs.
The relatively low morbidity/mortality of trimodality treatment
in patients with SSTs would be ascribed to the small size of the
irradiation field, which is a known predictive factor for radiation
toxicity. Theoretically, it would allow escalation of the radiation
dose, however, intensification of chemotherapy and not radio-
therapy should be the next logical step for further improvement
of the results, because the relapse pattern in these cases is
predominantly represented by distant metastases (Rusch et al,
2001; Kunitoh et al, 2003). Brain metastasis is also a challenging
problem in cases with SSTs, and PCI may have a role in the
management of these patients.
T4 tumours (other than SSTs)
Induction chemoradiotherapy might be beneficial for patients
with other T4 diseases, which invade the major vessels or organs.
Clinical response to the induction therapy may allow the surgeons
to resect the initially unresectable tumour. However, surgical
resection of T4 lung cancer, involving the carina, atrium, and/or
vena cava, is technically challenging, and surgical morbidity is still
high even for surgery alone (Tsuchiya et al, 1994). Grunenwald
et al (2001) reported a surgical mortality after chemoradiotherpy
of 7% and 5-year survival rate of 19%. As mediastinal cleaning by
induction therapy was reported to be prognostic, patients with
T4N0-1 disease might be good candidates for an attempt of this
approach. However, this remains to be confirmed in a prospective
study.
SUMMARY AND CONCLUSIONS
Optimal management of patients undergoing trimodality
treatment
The trimodality approach, although it is sometimes highly
effective, poses substantial risks to the patients. The risk/benefit
ratio must be carefully evaluated on an individual basis (Figures 1
and 2).
As the candidates for this treatment approach have locally
advanced disease, potential distant metastasis should be excluded
Figure 1 Management of N2 disease patients potentially indicated for
trimodality.
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and whole-body PET scans, before the initiation of therapy. After
the induction therapy, in addition to re-staging of the local disease
by CT imaging, brain MRI should be repeated, considering the
high risk of brain metastasis.
Although downstaging of the tumour after induction chemo-
radiotherapy sometimes does occur, physicians should not enrol
patients with technically unresectable disease at presentation, with
the hope of conversion of unresectable to resectable disease after
induction therapy. The exception, of course, is SST, in which
apparently unresectable T4 disease at presentation does not
represent a contraindication to trimodality treatment aimed at
complete resection (Rusch et al, 2001; Kunitoh et al, 2003). There
are no data on the results of trimodality treatment in cases of SSTs
with N2 disease, therefore, this approach cannot yet be recom-
mended for these patients at present.
Right pneumonectomy after induction chemoradiotherapy has
been reported to be associated with unacceptably high surgical
morbidity/mortality (Albain et al, 2005), and patients in whom
a right pneumonectomy for R0 resection would be indicated
should be very cautiously evaluated to determine whether or not
they might be suitable candidates for the trimodality approach.
Physicians should also be discouraged from considering the
trimodality approach for such a patient in the hope of downstaging
of the tumour with induction therapy.
Conclusions
For locally advanced NSCLC patients with clinical N2 disease, the
trimodality approach, although promising, should still be con-
sidered as investigational therapy. The suitability of a given patient
for this therapy must be meticulously determined by surgeons,
radiation oncologists, medical oncologists and chest physicians.
For SSTs, the trimodality approach can now be considered as
standard therapy, but it should be managed by an experienced
multimodality team as the risk remains substantial, with a
treatment-related death rate of 4%. Enrolment of patients into
clinical trials is strongly encouraged as there still remain numerous
unanswered questions.
REFERENCES
Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi III AT, Weick JK,
Lonchyna VA, Presant CA, McKenna RJ, Gandara DR (1995) Concurrent
cisplatin/etoposide plus chest radiotherapy followed by surgery for
stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results
of Southwest Oncology Group phase II study 8805. J Clin Oncol 13:
1880–1892
Albain KS, Swann RS, Rusch VR, Turrisi AT, Shepherd FA, Smith CJ,
Gandara DR, Johnson DH, Green MR, Miller RC (2005) Phase III study
of concurrent chemotherapy and radiotherapy vs chemotherapy and
radiotherapy followed by surgical resection for stageIIIA(pN2) non-
small cell lung cancer: Outcomes update of North American Inter-
group: Intergroup trial 0139. Proc Am Soc Clin Oncol 23: 624S
(abstr 7014)
Cerfolio RJ, Bryant AS, Spencer SA, Bartolucci AA (2005) Pulmonary
resection after high-dose and low-dose chest irradiation. Ann Thorac
Surg 80: 1224–1230; discussion 1230
Choi NC, Carey RW, Daly W, Mathisen D, Wain J, Wright C, Lynch T,
Grossbard M, Grillo H (1997) Potential impact on survival of improved
tumour downstaging and resection rate by preoperative twice-daily
radiation and concurrent chemotherapy in stage IIIA non-small-cell lung
cancer. J Clin Oncol 15: 712–722
Daly BD, Fernando HC, Ketchedjian A, Dipetrillo TA, Kachnic LA, Morelli
DM, Shemin RJ (2006) Pneumonectomy after high-dose radiation and
concurrent chemotherapy for nonsmall cell lung cancer. Ann Thorac
Surg 82: 227–231
Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B,
Braun D, Breton JL, Lemarie E, Gouva S, Paillot N, Brechot JM, Janicot H,
Lebas FX, Terrioux P, Clavier J, Foucher P, Monchatre M, Coetmeur D,
Level MC, Leclerc P, Blanchon F, Rodier JM, Thiberville L, Villeneuve A,
Westeel V, Chastang C (2002) Preoperative chemotherapy followed by
surgery compared with primary surgery in resectable stage I (except
T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 20: 247–253
Deslauriers J, Gregoire J, Jacques LF, Piraux M, Guojin L, Lacasse Y (2004)
Sleeve lobectomy vs pneumonectomy for lung cancer: a comparative
analysis of survival and sites or recurrences. Ann Thorac Surg 77:
1152–1156
Deutsch M, Crawford J, Leopold K, Wolfe W, Foster W, Herndon J,
Blackwell S, Yost R (1994) Phase II study of neoadjuvant chemotherapy
and radiation therapy with thoracotomy in the treatment of clinically
staged IIIA non-small cell lung cancer. Cancer 74: 1243–1252
Dillman RO, Herndon J, Seagren SL, Eaton Jr WL, Green MR (1996)
Improved survival in stage III non-small-cell lung cancer: seven-year
Figure 2 Management of SST patients potentially indicated for trimodality.
Trimodality in NSCLC
H Kunitoh and K Suzuki
1502
British Journal of Cancer (2007) 96(10), 1498–1503 & 2007 Cancer Research UKfollow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl
Cancer Inst 88: 1210–1215
Doddoli C, Thomas P, Thirion X, Seree Y, Giudicelli R, Fuentes P (2001)
Postoperative complications in relation with induction therapy for lung
cancer. Eur J Cardiothorac Surg 20: 385–390
Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-
Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C,
Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A,
Jassem J, Koubkova L, His P, Riggi M, Hurteloup P (2006) Adjuvant
vinorelbine plus cisplatin vs observation in patients with completely
resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine
International Trialist Association (ANITA)): a randomised controlled
trial. Lancet Oncol 7: 719–727
Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H,
Krause B, Mueller MR, Stahl M, Flasshove M, Budach V, Greschuchna D,
Konietzko N, Sack H, Seeber S (1998) Preoperative chemotherapy
followed by concurrent chemoradiation therapy based on hyperfractio-
nated accelerated radiotherapy and definitive surgery in locally advanced
non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol
16: 622–634
Faber LP, Kittle CF, Warren WH, Bonomi PD, Taylor SGT, Reddy S, Lee MS
(1989) Preoperative chemotherapy and irradiation for stage III non-small
cell lung cancer. Ann Thorac Surg 47: 669–675; discussion; 676–677
Fleck J, Camargo J, Godoy D, Teixeira P, Braga-Filho A, Barietta A,
Ferreira P (1993) Chemoradiation therapy vs chemotherapy alone as
a neoadjuvant treatment for stage III non–small-cell lung cancer:
preliminary report of a phase III prospective randomized trial. Proc Am
Soc Clin Oncol 12: 333 (abstr 1108)
Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S,
Katagami N, Ariyoshi Y (1999) Phase III study of concurrent vs
sequential thoracic radiotherapy in combination with mitomycin,
vindesine, and cisplatin in unresectable stage III non-small-cell lung
cancer. J Clin Oncol 17: 2692–2699
Grunenwald DH, Andre F, Le Pechoux C, Girard P, Lamer C, Laplanche A,
Tarayre M, Arriagada R, Le Chevalier T (2001) Benefit of surgery after
chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung
cancer. J Thorac Cardiovasc Surg 122: 796–802
Katakami N, Okazaki M, Nishiuchi S, Fukuda H, Horikawa T, Nishiyama H,
Inui H, Bando K (1998) Induction chemoradiotherapy for advanced
stage III non-small cell lung cancer: long-term follow-up in 42 patients.
Lung Cancer 22: 127–137
Kunitoh H, Kato H, Tsuboi M, Ishizuka N, Tsuchiya R, Ichinose Y,
Katakami N, Saijo N (2003) A phase II trial of pre-operative
chemoradiotherapy followed by surgical resection in pancoast tumours:
initial report of Japan Clinical Oncology Group trial (JCOG 9806).
Proc Am Soc Clin Oncol 22: 634 (abstr 2549)
Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M,
Lacombe-Terrier MJ, Douillard JY, Laplanche A (1991) Radiotherapy
alone vs combined chemotherapy and radiotherapy in nonresectable
non-small-cell lung cancer: first analysis of a randomized trial in 353
patients. J Natl Cancer Inst 83: 417–423
Martin J, Ginsberg RJ, Abolhoda A, Bains MS, Downey RJ, Korst RJ, Weigel
TL, Kris MG, Venkatraman ES, Rusch VW (2001) Morbidity and
mortality after neoadjuvant therapy for lung cancer: the risks of right
pneumonectomy. Ann Thorac Surg 72: 1149–1154
Mateu-Navarro M, Rami-Porta R, Bastus-Piulats R, Cirera-Nogueras L,
Gonzalez-Pont G (2000) Remediastinoscopy after induction chemother-
apy in non-small cell lung cancer. Ann Thorac Surg 70: 391–395
Pisters KM, Ginsberg RJ, Giroux DJ, Putnam Jr JB, Kris MG, Johnson DH,
Roberts JR, Mault J, Crowley JJ, Bunn Jr PA (2000) Induction
chemotherapy before surgery for early-stage lung cancer: a novel
approach. Bimodality lung oncology team. J Thorac Cardiovasc Surg
119: 429–439
Pottgen C, Levegrun S, Theegarten D, Marnitz S, Grehl S, Pink R, Eberhardt
W, Stamatis G, Gauler T, Antoch G, Bockisch A, Stuschke M (2006)
Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/
computed tomography in non-small-cell lung cancer for prediction of
pathologic response and times to relapse after neoadjuvant chemoradio-
therapy. Clin Cancer Res 12: 97–106
Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, Mate JL,
Li S, Roig J, Olazabal A (1994) A randomized trial comparing
preoperative chemotherapy plus surgery with surgery alone in patients
with non-small-cell lung cancer. N Engl J Med 330: 153–158
Roth JA, Fossella F, Komaki R, Ryan MB, Putnam Jr JB, Lee JS, Dhingra H,
De Caro L, Chasen M, McGavran M (1994) A randomized trial compa-
ring perioperative chemotherapy and surgery with surgery alone in
resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86:
673–680
Rusch VW, Albain KS, Crowley JJ, Rice TW, Lonchyna V, McKenna Jr R,
Livingston RB, Griffin BR, Benfield JR (1993) Surgical resection of stage
IIIA and stage IIIB non-small-cell lung cancer after concurrent induction
chemoradiotherapy. A Southwest Oncology Group trial. J Thorac
Cardiovasc Surg 105: 97–104; discussion; 104–106
Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Johnson D,
Goldberg M, Detterbeck F, Shepherd F, Burkes R, Winton T, Deschamps
C, Livingston R, Gandara D (2001) Induction chemoradiation and
surgical resection for non-small cell lung carcinomas of the superior
sulcus: initial results of Southwest Oncology Group Trial 9416
(Intergroup Trial 0160). J Thorac Cardiovasc Surg 121: 472–483
Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, Emami B,
Curran WJ, Byhardt RW, Turrisi AT (1995) Radiation therapy oncology
group (RTOG) 88-08 and eastern cooperative oncology group (ECOG)
4588: preliminary results of a phase III trial in regionally advanced,
unresectable non-small-cell lung cancer. J Natl Cancer Inst 87: 198–205
Sauvaget J, Rebischung JL, Vannetzel JM (2000) Phase III study of
neo-adjuvant MVP vs MVP plus chemo-radiotherapy in stage III NSCLC.
Proc Am Soc Clin Oncol 19: 495a (abstr1935)
Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J,
van Houtte P, Kiekpatrick A, Koolen M, Maat B, Nijs A (1992) Effects of
concomitant cisplatin and radiotherapy on inoperable non-small-cell
lung cancer. N Engl J Med 326: 524–530
Semik M, Riesenbeck D, Linder A, Schmid C, Hoffknecht P, Heinecke A,
Scheld H, Thomas M (2004) Preoperative chemotherapy with and
without additional radiochemotherapy: benefit and risk for surgery
of stage III non-small cell lung cancer. Eur J Cardiothorac Surg 26:
1205–1210
Sonett JR, Suntharalingam M, Edelman MJ, Patel AB, Gamliel Z, Doyle A,
Hausner P, Krasna M (2004) Pulmonary resection after curative intent
radiotherapy (459Gy) and concurrent chemotherapy in non-small-cell
lung cancer. Ann Thorac Surg 78: 1200–1205; discussion; 1206
Stamatis G, Djuric D, Eberhardt W, Pottken C, Zaboura G, Fechner S,
Fujimoto T (2002) Postoperative morbidity and mortality after induction
chemoradiotherapy for locally advanced lung cancer: an analysis of 350
operated patients. Eur J Cardiothorac Surg 22: 292–297
Stuschke M, Eberhardt W, Po ¨ttgen C, Stamatis G, Wilke H, Stu ¨ben G,
Sto ¨blen F, Wilhelm HH, Menker H, Teschler H, Mu ¨ller RD, Budach V,
Seeber S, Sack H (1999) Prophylactic cranial irradiation in locally
advanced non-small-cell lung cancer after multimodality treatment:
long-term follow-up and investigations of late neuropsychologic effects.
J Clin Oncol 17: 2700–2709
Suzuki K, Nagai K, Yoshida J, Nishimura M, Takahashi K, Nishiwaki Y
(1999) The prognosis of surgically resected N2 non-small cell lung
cancer: the importance of clinical N status. J Thorac Cardiovasc Surg 118:
145–153
The International Adjuvant Lung Cancer Trial Collaborative Group (2004)
Cisplatin-based adjuvant chemotherapy in patients with completely
resected non-small-cell lung cancer. N Engl J Med 350: 351–360
Thomas M, Ru ¨be C, Semik M, von Eiff M, Freitag L, Macha HN, Wagner W,
Klinke F, Scheld HH, Willich N, Berdel WE, Junker K (1999) Impact of
preoperative bimodality induction including twice-daily radiation on
tumour regression and survival in stage III non-small-cell lung cancer.
J Clin Oncol 17: 1185–1193
Tsuchiya R, Asamura H, Kondo H, Goya T, Naruke T (1994) Extended
resection of the left atrium, great vessels, or both for lung cancer. Ann
Thorac Surg 57: 960–965
Watanabe S, Asamura H, Suzuki K, Tsuchiya R (2004) Recent results
of postoperative mortality for surgical resections in lung cancer.
Ann Thorac Surg 78: 999–1002; discussion 1002–1003
Trimodality in NSCLC
H Kunitoh and K Suzuki
1503
British Journal of Cancer (2007) 96(10), 1498–1503 & 2007 Cancer Research UK